biote Corp(BTMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 9.72 | EPS (ttm) | 0.12 | Insider Own | 18.76% | Shs Outstand | 27.7M | Perf Week | 7.34% |
| Market Cap | 0.04B | Forward P/E | 4.93 | EPS next Y | 763.64% | Insider Trans | 2% | Shs Float | 23.3M | Perf Month | -3.31% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.01 | Inst Own | 61.97% | Short Float | 5.07% | Perf Quarter | -48% |
| Income | 0.01B | P/S | 0.23 | EPS this Y | -96.28% | Inst Trans | -9.26% | Short Ratio | 5.57 | Perf Half Y | -47.3% |
| Sales | 0.18B | P/B | - | EPS next 5Y | -12.25% | ROA | 5.67% | Short Interest | 1.18M | Perf YTD | -55% |
| Book/sh | -2.38 | P/C | 3.76 | EPS past 3/5Y | - 11.37% | ROE | - | 52W High | -60.74% ($2.98) | Perf Year | -56.18% |
| Cash/sh | 0.31 | P/FCF | 2.12 | Sales past 3/5Y | 5.23% 10.52% | ROIC | 9.92% | 52W Low | 17% ($1.00) | Perf 3Y | -77.1% |
| Dividend Est. | - | EV/EBITDA | 6.44 | EPS Y/Y TTM | -82.99% | Gross Margin | 66.93% | Volatility(W/M) | 9.79% 9.33% | Perf 5Y | -88% |
| Dividend TTM | - | EV/Sales | 0.91 | Sales Y/Y TTM | -7.81% | Oper. Margin | 12.03% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.81 | EPS Q/Q | -328.61% | Profit Margin | 3.19% | RSI (14) | 48.94 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.43 | Sales Q/Q | -9.48% | SMA20 | 4.77% ($1.12) | Beta | 1.73 | Target Price | $2.61 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/4 | SMA50 | -10.13% ($1.3) | Rel Volume | 0.6 | Prev Close | $1.15 |
| Employees | 223 | LT Debt/Eq | - | EPS/Sales Surpr. | -961.42% -4.17% | SMA200 | -36.22% ($1.83) | Avg Volume(3M) | 0.21M | Price | $1.17 |
| IPO | 2021/4/28 | Option/Short | No/Yes | Trades | 335 | Volume | 127,002 | Change | 1.74% |
💊 This is a US healthcare company that supplies hormone balance management pellet procedures and related nutritional supplements to a network of medical professionals. Founded in 2011 by Gary Donovitz, the company operates a business model that bundles products, education, and practice expansion support to enable its affiliated medical practitioners to offer pellet procedures to their patients.
Over the past 1 year, on the lower side
61% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
Next earnings report: November 4
5 days to go.
BTMD makes money exceptionally well
Of every $100 in sales, $12.03 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -96.3% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $644. Peers typically go for $1,321. Compared with its own 3-year average, it is 32% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 62.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #41 of 48 in the industry
Based on market cap of $42M.
FAQ
What kind of company is BTMD?
BTMD belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of BTMD?
The market cap of BTMD is approximately $42M, ranking 4,939 within its sector.
What is the P/E ratio of BTMD?
BTMD has a P/E ratio of approximately 9.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BTMD?
BTMD has recorded a 52-week high of $2.98 and a low of $1.00.
